Trials & Filings

Keryx NDA Accepted for CKD Treatment

Zerenex submitted in August

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Keryx Biopharmaceuticals‘ NDA for Zerenex (ferric citrate coordination complex) has been accepted for filing by the FDA. The acceptance indicates that the FDA has determined that the application is sufficiently complete to permit a substantive review. The company’s NDA, submitted on August 7, 2013, seeks approval for the marketing and sale of Zerenex as a treatment for elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters